Wall Street brokerages expect that Sarepta Therapeutics Inc (NASDAQ:SRPT) will report earnings of ($0.34) per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Sarepta Therapeutics’ earnings. The lowest EPS estimate is ($0.52) and the highest is ($0.21). Sarepta Therapeutics posted earnings of ($0.78) per share during the same quarter last year, which suggests a positive year over year growth rate of 56.4%. The company is expected to report its next earnings report on Wednesday, October 24th.

On average, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($2.98) to ($1.28). For the next financial year, analysts anticipate that the company will report earnings of ($1.17) per share, with EPS estimates ranging from ($2.27) to ($0.45). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.99). Sarepta Therapeutics had a negative net margin of 89.64% and a negative return on equity of 19.34%. The company had revenue of $73.53 million for the quarter, compared to the consensus estimate of $71.53 million. During the same quarter in the previous year, the business earned ($0.48) earnings per share. Sarepta Therapeutics’s revenue was up 110.0% compared to the same quarter last year.

Several equities research analysts recently commented on the company. William Blair reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, June 19th. HC Wainwright increased their price objective on Sarepta Therapeutics from $96.00 to $267.00 and gave the company a “buy” rating in a research report on Tuesday, June 19th. BTIG Research assumed coverage on Sarepta Therapeutics in a research report on Friday, June 15th. They set a “buy” rating and a $120.00 price objective on the stock. WBB Securities reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Wednesday, June 20th. Finally, Needham & Company LLC increased their price objective on Sarepta Therapeutics from $109.00 to $204.00 and gave the company a “buy” rating in a research report on Wednesday, June 20th. Three investment analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and two have given a strong buy rating to the company. Sarepta Therapeutics currently has an average rating of “Buy” and an average price target of $154.21.

In other Sarepta Therapeutics news, Director Richard Barry sold 75,000 shares of the firm’s stock in a transaction dated Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total value of $9,775,500.00. Following the transaction, the director now directly owns 3,170,432 shares of the company’s stock, valued at $413,234,106.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Douglas S. Ingram bought 16,000 shares of the company’s stock in a transaction on Wednesday, August 15th. The stock was purchased at an average cost of $125.26 per share, for a total transaction of $2,004,160.00. Following the completion of the transaction, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at approximately $50,010,055. The disclosure for this purchase can be found here. Insiders sold 158,782 shares of company stock worth $21,237,444 over the last three months. Insiders own 7.90% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Xact Kapitalforvaltning AB boosted its position in Sarepta Therapeutics by 5.7% in the second quarter. Xact Kapitalforvaltning AB now owns 9,202 shares of the biotechnology company’s stock worth $1,216,000 after purchasing an additional 500 shares during the last quarter. Principal Financial Group Inc. boosted its position in Sarepta Therapeutics by 2.7% in the first quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock worth $1,478,000 after purchasing an additional 530 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in Sarepta Therapeutics by 0.5% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 145,854 shares of the biotechnology company’s stock worth $19,279,000 after purchasing an additional 709 shares during the last quarter. SeaCrest Wealth Management LLC raised its stake in shares of Sarepta Therapeutics by 59.0% in the second quarter. SeaCrest Wealth Management LLC now owns 2,326 shares of the biotechnology company’s stock worth $307,000 after buying an additional 863 shares during the period. Finally, Commonwealth Equity Services LLC raised its stake in shares of Sarepta Therapeutics by 11.0% in the second quarter. Commonwealth Equity Services LLC now owns 8,989 shares of the biotechnology company’s stock worth $1,188,000 after buying an additional 892 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:SRPT traded up $2.55 on Thursday, hitting $152.76. 1,199,217 shares of the company traded hands, compared to its average volume of 810,309. Sarepta Therapeutics has a 52 week low of $42.97 and a 52 week high of $176.50. The company has a debt-to-equity ratio of 0.62, a quick ratio of 9.89 and a current ratio of 10.88.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Featured Article: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.